Okan Gultekin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Okan Gultekin has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Kaisa Lehti
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
40 shared publications - Lidia Moyano-Galceran
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
31 shared publications - Joseph Woodward Carlson
Department of Oncology-Pathology, Karolinska Institutet
21 shared publications Esther Schoutrop
17 shared publications- Ibrahim El-Serafi
Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
17 shared publications - Isabelle Magalhaes
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
17 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106135
A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response
- 2 February 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106135
Open AccessA 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response
- Open Access
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Biomimetic organo-hydrogels reveal the adipose tissue local mechanical anisotropy regulates ovarian cancer invasion
High-grade serous ovarian cancer, the most common and aggressive ovarian cancer subtype, frequently metastasises to visceral adipose tissues. In these tissues, the extracellular matrix through which ovarian cancer cells migrate is constrained by the presence and preponderance of adipocytes. How cells migrate in this unique environment is not known, yet critical to understanding metastatic progression. To study these processes, we developed biomimetic organo-hydrogels that recreate structural, mechanical, and biochemical properties of human adipose tissues. We show that ovarian cancer cells present invasive tropism towards organo-hydrogels, replicating the behaviour observed in native adipose tissues. This migration is facilitated by the mechanical anisotropy and microstructure of organo-hydrogels and adipose tissues, allowing the formation of migratory tracks. These results highlight the contribution of adipocytes to tissue biophysical features as a key regulatory factor of ovarian cancer cell migration and demonstrate that organo-hydrogels are particularly relevant tools to develop in vitro models of complex tissue architectures with high cellularity.
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessBiomimetic organo-hydrogels reveal the adipose tissue local mechanical anisotropy regulates ovarian cancer invasion
High-grade serous ovarian cancer, the most common and aggressive ovarian cancer subtype, frequently metastasises to visceral adipose tissues. In these tissues, the extracellular matrix through which ovarian cancer cells migrate is constrained by the presence and preponderance of adipocytes. How cells migrate in this unique environment is not known, yet critical to understanding metastatic progression. To study these processes, we developed biomimetic organo-hydrogels that recreate structural, mechanical, and biochemical properties of human adipose tissues. We show that ovarian cancer cells present invasive tropism towards organo-hydrogels, replicating the behaviour observed in native adipose tissues. This migration is facilitated by the mechanical anisotropy and microstructure of organo-hydrogels and adipose tissues, allowing the formation of migratory tracks. These results highlight the contribution of adipocytes to tissue biophysical features as a key regulatory factor of ovarian cancer cell migration and demonstrate that organo-hydrogels are particularly relevant tools to develop in vitro models of complex tissue architectures with high cellularity.
- Open Access
Recognition of Ovarian Tumor-Derived Non-canonical Peptide Induces Memory-Like Features in Natural Killer Cells
Immune cell-based immunotherapy has emerged as a promising strategy for both hematologic malignancies and solid tumors. The adaptive properties of T and B cells, namely, antigen specificity and long-term immune memory, form the foundation of approaches such as chimeric antigen receptor (CAR) T-cell therapy and tumor vaccines. In contrast, natural killer (NK) cells, traditionally classified as innate lymphocytes, have been appreciated primarily for their immediate cytotoxicity against tumor cells, but not for long-term memory-like responses. Recent evidence has revealed a subset of NK cells defined as adaptive NK cells (aNK) capable of developing adaptive features, particularly in response to cytomegalovirus (CMV) primarily, and more recently, to ovarian tumor-derived antigens. However, whether tumor-derived peptides can specifically induce NK cell memory, and the corresponding interaction patterns, remains largely unexplored. In this study, we employed a proteogenomic approach combining RNA sequencing (RNA-seq) with HLA-E immunoprecipitation to identify both canonical and non-canonical peptides presented by primary ovarian tumor cells. Among four tumor-derived neo-antigenic peptides, the 9-mer peptide APAPAPAPL demonstrated the strongest binding affinity to HLA-E and engagement with the NK receptors NKG2C/A. Functional in vitro assays confirmed that this peptide could induce memory-like NK cell responses, including antigen-specific recall activity and enhanced tumor cytotoxicity. Furthermore, structural modeling using AutoDock Vina and Rosetta Dock illustrated that peptides with similar binding capacity shared conserved interaction patterns and docking orientations. Together, this systemic study highlights a novel mechanism for inducing NK cell memory through tumor-derived neoantigens. It also paves the way for the development of NK cell-targeted cancer vaccines, representing a new direction in tumor immunotherapy beyond conventional T cell-centered strategies.
Open AccessRecognition of Ovarian Tumor-Derived Non-canonical Peptide Induces Memory-Like Features in Natural Killer Cells
Immune cell-based immunotherapy has emerged as a promising strategy for both hematologic malignancies and solid tumors. The adaptive properties of T and B cells, namely, antigen specificity and long-term immune memory, form the foundation of approaches such as chimeric antigen receptor (CAR) T-cell therapy and tumor vaccines. In contrast, natural killer (NK) cells, traditionally classified as innate lymphocytes, have been appreciated primarily for their immediate cytotoxicity against tumor cells, but not for long-term memory-like responses. Recent evidence has revealed a subset of NK cells defined as adaptive NK cells (aNK) capable of developing adaptive features, particularly in response to cytomegalovirus (CMV) primarily, and more recently, to ovarian tumor-derived antigens. However, whether tumor-derived peptides can specifically induce NK cell memory, and the corresponding interaction patterns, remains largely unexplored. In this study, we employed a proteogenomic approach combining RNA sequencing (RNA-seq) with HLA-E immunoprecipitation to identify both canonical and non-canonical peptides presented by primary ovarian tumor cells. Among four tumor-derived neo-antigenic peptides, the 9-mer peptide APAPAPAPL demonstrated the strongest binding affinity to HLA-E and engagement with the NK receptors NKG2C/A. Functional in vitro assays confirmed that this peptide could induce memory-like NK cell responses, including antigen-specific recall activity and enhanced tumor cytotoxicity. Furthermore, structural modeling using AutoDock Vina and Rosetta Dock illustrated that peptides with similar binding capacity shared conserved interaction patterns and docking orientations. Together, this systemic study highlights a novel mechanism for inducing NK cell memory through tumor-derived neoantigens. It also paves the way for the development of NK cell-targeted cancer vaccines, representing a new direction in tumor immunotherapy beyond conventional T cell-centered strategies.
- Open Access
- 15 July 2025
- Published by Elsevier in Translational Oncology
- Vol. 59, 102462
Systemic and tumor-specific inflammatory markers VCAM-1 and ICAM-1 as indicators of extent of surgery and oncologic outcome in advanced ovarian cancer
- 15 July 2025
- Published by Elsevier in Translational Oncology
- Vol. 59, 102462
Open AccessSystemic and tumor-specific inflammatory markers VCAM-1 and ICAM-1 as indicators of extent of surgery and oncologic outcome in advanced ovarian cancer
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Adaptive NK Cells Exhibit Tumor-Specific Immune Memory and Cytotoxicity in Ovarian Cancer
DEGs for all myeloid cell clusters
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Adaptive NK Cells Exhibit Tumor-Specific Immune Memory and Cytotoxicity in Ovarian Cancer
DEGs for all myeloid cell clusters